Project Grant Q184A070077

This $673,500 Project Grant from the National Institutes of Health's National Institute on Alcohol Abuse and Alcoholism will fund Amygdala Neurosciences, Inc. to develop new, potent, selective, and reversible inhibitors of aldehyde dehydrogenase 2 (ALDH2) for the treatment of alcohol use disorder. The goal is to implement an innovative screening technology to discover novel compounds that reduce craving and alcohol consumption by selectively inhibiting ALDH2 in a reversible manner, avoiding...

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $282,353 Project Grant under the Alcohol Research Programs (CFDA 93.273) to the Public Health Institute (PHI) in California. The funding will support a secondary analysis project titled "Blood Alcohol Content Limit Laws and Alcohol-Related Outcomes" from September 2025 to August 2027. The project aims to examine how blood alcohol content (BAC) limit laws for driving are related to alcohol consumption and...

The National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), awarded a $711,938 Project Grant to Research Triangle Institute (RTI International) on September 20, 2025. The goal of this 5-year grant is to conduct a hybrid implementation effectiveness cluster randomized trial of a mobile health (mHealth) intervention called BIPAS (Better Informed Parents Keeping Adolescents Safe from Alcohol) to help parents prevent early-onset alcohol use in...

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $399,048 Project Grant under the Alcohol Research Programs (CFDA 93.273) to the Rochester Institute of Technology (RIT) to examine behavioral and electrophysiological cue reactivity in young adult binge drinkers. The study will compare responses to uni- and multisensory alcohol and neutral cues that vary in degree of realistic appearance, and explore the effects of multisensory congruence on cue responses. The project...

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $914,324 Project Grant under the Alcohol Research Programs (CFDA 93.273) to Demerx, Inc., a Miami-based biotechnology company, for the investigational new drug development of noribogaine for the treatment of alcohol use disorder (AUD). The grant supports Demerx's research efforts to advance noribogaine, a novel "psychoplastogen" therapeutic agent, through preclinical studies and early clinical trials. Key...

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $413,496 Project Grant under the Alcohol Research Programs (CFDA 93.273) to The Research Foundation for the State University of New York (RF SUNY), doing business as Sponsored Projects Services. This grant, titled "Enhancing Alcohol Use Disorder Recovery by Capturing the Dynamics of Psychological Well-Being in Daily Life," aims to better understand and assess psychological well-being (PWB) among individuals in...

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $735,930 Project Grant under the Alcohol Research Programs (CFDA 93.273) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct a feasibility and acceptability study of a large language model-based conversational agent for brief alcohol intervention among emerging adults aged 18-29. The project aims to develop, validate, and conduct an open trial of the conversational...

This federal Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), provides $618,904 to Real Recovery VR, Inc. to develop a virtual reality (VR) platform that counselors can use to enhance treatment techniques and improve outcomes among those with alcohol use disorder (AUD). The project aims to leverage VR technology to help AUD patients learn and practice coping skills in realistic simulated environments,...

This Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273) federal grant program, is funding a 12-week randomized controlled trial to evaluate the efficacy of probenecid, a pannexin 1 channel inhibitor, in reducing alcohol craving and consumption in 120 individuals with alcohol use disorder. The $733,137 award, granted on September 18, 2025, aims to replicate previous findings from the awardee's rodent and human...

The National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), awarded a $739,041 Project Grant to the University of Rochester to develop and initiate testing of a scalable person-centered planning (PCP) intervention to support quality of life for adolescents and adults with Fetal Alcohol Spectrum Disorders (FASD). The project aims to systematically adapt and test the PCP intervention for the FASD population, leveraging technology to overcome...